RHABDURGENCE: Support for the Rhabdomyolysis in an Emergency Department

Sponsor
Groupe Hospitalier Paris Saint Joseph (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02896517
Collaborator
(none)
0
1

Study Details

Study Description

Brief Summary

Rhabdomyolysis is a common condition in the UAA. Support is heterogeneous, it is in most cases a mass hyperhydration. The idea is to initially with an EPP simultaneously screened for the most affected by this disease and aggravating factors population, associated comorbidities.

The rhabdomyolysis prognosis depends mainly on the etiology and associated comorbidities.

  • Acute renal failure and hyperkalemia are the major complications that worsen the prognosis.

  • In most cases, acute renal failure is reversible. Acute renal failure caused by renal vasoconstriction with ischemia, precipitation of myoglobin in the tubules and direct cytotoxic action of myoglobin.

If the prime mover of rhabdomyolysis is ischemia (or hypoxia) cell, we now know that the tissue damage is greatly aggravated during muscle reperfusion, creating ischemia-reperfusion. Reperfusion will not only cause the release into the bloodstream of the cell contents myocytes but also an increase in necrotic areas. Indeed, the massive arrival of oxygen at the myocyte will cause significant production of free radicals, increasing their toxic effects.

Predictive factors of acute renal failure is creatinine and urea. The urine alkalinisation by bicarbonates is questionable oral alkalizing seems to be an alternative when possible (oral alkaline solution) but not used to this day.

The track N-acetyl cysteine as an antioxidant that can possibly have an effect on release of the free radicals during reperfusion by decreasing their toxicity is still not considered clinically.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Main objective / secondary:
    Evaluation of current professional practice:
    1. Identify the most common etiologies encountered in our SAU. II. Identify the / types of people most affected by this disease III. Detect the most common complications of H0 support and evolution H48 if the patient not transferred IV. Evaluate the emergency treatment at the initial charge.
    Methodology :
    DESIGN:

    It is a non-interventional retrospective single-center study, within the Department of Emergency GHPSJ, to an EPP and output the results regarding the type of population most affected by this disease with the most common etiologies in our support (what we are doing).

    Time study:

    Study on patient records being passed on to the emergency 12 months out with a diagnosis of rhabdomyolysis.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    0 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Support for the Rhabdomyolysis in an Emergency Department
    Anticipated Study Start Date :
    Oct 1, 2016
    Anticipated Primary Completion Date :
    Oct 1, 2016
    Anticipated Study Completion Date :
    Oct 1, 2016

    Outcome Measures

    Primary Outcome Measures

    1. Assessment of change of patient complication by answering a questionary [Hour 0, Hour 48]

      Detect the most common complications of Hour 0 support and evolution Hour 48 if the patient not transferred. Hour 0 support and evolution at Hour 48

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All adults with CPK greater than 5N or 500 IU / L in sera to emergencies
    Exclusion Criteria:
    • No exclusion criteria

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France France 75014

    Sponsors and Collaborators

    • Groupe Hospitalier Paris Saint Joseph

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Groupe Hospitalier Paris Saint Joseph
    ClinicalTrials.gov Identifier:
    NCT02896517
    Other Study ID Numbers:
    • RHABDURGENCE
    First Posted:
    Sep 12, 2016
    Last Update Posted:
    Aug 13, 2018
    Last Verified:
    Aug 1, 2018
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 13, 2018